Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
ZOES / Zoe's Kitchen, Inc. / Vintage Capital Management LLC - SCHEDULE 13G (Passive Investment)

2018-06-28 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ZOES

2
ZOES / Zoe's Kitchen, Inc. / Vintage Capital Management LLC - SCHEDULE 13G (Passive Investment)

2018-06-28 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ZOES

1
ZOES / Zoe's Kitchen, Inc. S-8

2018-06-25 sec.gov
Document As filed with the Securities and Exchange Commission on June 25, 2018 Registration
ZOES

45
Habit Restaurants: Driving To Success

2018-06-22 seekingalpha
Any restaurant reporting negative comp sales isn't likely to get a lot of respect in the market regardless of the prevailing retail environment. The bullish case for Habit Restaurants (HABT) remains that the stock is too depressed based on a focus on the current climate in the restaurant sector.
SHAK HABT JACK ZOES CMG

5
ZOES / Zoe's Kitchen, Inc. 8-K (Current Report)

2018-06-19 sec.gov
Document UNITED STATES SECURITIES AND EX
ZOES

528
Stocks To Watch: Don't Sleep On Vienna

2018-06-16 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
NPSNY SYY RUTH LX MS DECK SRRK EQIX JACK MDT TACOW KNSA VZ ZOES FB CLPS QNST MCRI KR SMTC CCL RYDAF EVOP INTC DRRX ICLK MUSA ITUB BB UNFI RHT PTIE HLF JPM MU FNKO HBNC SBUX LOCO PLAY XOM TWX MS.PRE MS.PRF MS.PRG RDSB TOT RDSA MS.PRA SHAK HMNY SAFM BKS AAN OSTK GSKY INCY CTLR CCL BP MS.PRI GOOGL MS.PRK FLL RYDBF MKSI FITB CLR BB PPC BC NDLS DOGZ FND DRI SGBXQ FINL WGO COP XHR DAL ORCL DIS JASO F RDS.B RDS.A TACO DISH TMSR SPTN FDX VLO GOLF CHUY SNY CHEF W ITRM SGBX CVX SNE

2
New Strong Sell Stocks for May 31st

2018-05-31 zacks
Zoe's Kitchen, Inc. (ZOES - Free Report) is an operator of a chain of fast-casual restaurants. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.
VR PETQ ZOES VR.PRA VR.PRB

4
ZOES / Zoe's Kitchen, Inc. 8-K (Current Report)

2018-05-28 sec.gov
Document UNITED STATES
ZOES

4
Zoe's Kitchen (ZOES) Down on Wider-Than-Expected Loss in Q1

2018-05-27 zacks
Shares of Zoe's Kitchen, Inc. decreased 23.6% in after-hours trading on May 24, after the company reported weaker-than-expected first-quarter 2018 numbers. So far this year, the stock has declined 13.4% compared with the 1% fall of the industry it belongs to. Moreover, the company trimmed its guidance for 2018.
DUKH LMT DUK ZOES

55
What to Expect From Zoe's Kitchen (ZOES) in Q1 Earnings?

2018-05-18 zacks
Zoe's Kitchen, Inc. is slated to report first-quarter 2018 results on May 24, after market close.
DUKH AMAT DUK ZOES

0
ZOES / Zoe's Kitchen, Inc. DEFA14A

2018-04-24 sec.gov
Document UNITED STATES
ZOES

2
ZOES / Zoe's Kitchen, Inc. DEF 14A

2018-04-24 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ZOES

60
Chipotle Mexican Grill, Inc. Stock Has More Downside Ahead

2018-03-16 investorplace
Chipotle Mexican Grill, Inc. (NYSE:CMG) has seen some optimism lately. Chipotle stock has rallied 29% since early February. Of course, that optimism is relative: CMG stock had hit a five-year low before that rally.
YUM BOX JACK ZOES QSR MCD QSR.WI CMG

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

12h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 98979J109